CytoDyn Inc.’s (CYDY) New HIV Treatment Could Bring a Paradigm Shift in HIV Therapy
PRO 140 requires one dose a week, rather than daily pills Treatment has shown hardly any side-effects in clinical trials, while current HIV therapies may cause mild to severe side-effects CytoDyn’s treatment is simple for patients to administer with hardly any toxicity Significant advantages of PRO 140, CytoDyn Inc.’s (OTCQB: CYDY) viral-entry inhibitor, over drugs currently used in HIV treatment therapies have been reported, namely showing little if any toxicity or side-effects in treated patients to date, ease of administration (once weekly dosing) and a lack of HIV resistance developing to the treatment. Although there are several promising HIV therapies…